|Bid||0.0000 x 42300|
|Ask||0.0000 x 45100|
|Day's range||1.3500 - 1.4600|
|52-week range||1.1200 - 2.5450|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.38|
Vivici BV, an innovative B2B ingredients startup company using precision fermentation to make animal-free dairy proteins, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo's extensive capabilities in strain engineering, optimization and performance, to develop and commercialize a next generation of functional alternative protein.
XWELL, Inc. Brands XWELL, Inc. Brands Airport Spas Deliver Strong 39% Year-Over-Year Q3 Revenue GrowthNaples Wax Center Acquisition Accelerates Future Off-Airport Growth OpportunitiesFurther Airport Spa Expansion Internationally NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter ended September 30, 2023. Financial and Business Highlights: The Compa
Foremost Farms USA, a world-class producer of cheese, butter, and dairy ingredients supplied to national and international markets, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to use advances in biotechnology to enable domestic, sustainable biomanufacturing of materials from dairy co-products to benefit the environment, family farms and the dairy industry as a whole.